Secretome Therapeutics Granted Composition of Matter Patents

Secretome Therapeutics, a biotechnology company developing therapies from neonatal cardiac progenitor cells (nCPCs), announced today the allowance of a composition of matter patent for its lead asset, STM-01, an innovative nCPC-derived product. Recently, a similar patent was also granted for STM-21, the company's primary secretome product sourced from nCPCs. These patents significantly bolster Secretome's intellectual property portfolio as the company progresses its pipeline. 

Composition of matter patents offer extensive protection over the molecular structure of therapeutic products. Secretome Therapeutics is currently the exclusive holder of nCPC-related intellectual property, with patent protection extending through 2035.

Learn more